+34 914 524 941    info@algenex.com

About ALGENEX

Inspiring the future of biologics production

Algenex is a disruptive technology platform for the production of biologics.  The core current focus is Animal Health vaccines, where Algenex has worked with multiple large international players. The platform is fully functional and IP protected. Algenex is based in Madrid, Spain.
Algenex is a disruptive technology platform for the production of biologics.  The core current focus is Animal Health vaccines, where Algenex has worked with multiple large international players. The platform is fully functional and IP protected. Algenex is based in Madrid, Spain.

Management Team

General Manager

qodef-team-image
General Manager

Claudia Jimenez

Claudia has 20 years of experience and a proven record of accomplishment in corporate development, investor relations and communications. She started her career in corporate finance at WestLB AG in Germany, where she managed mergers and acquisition (M&A) projects across various industries. Following the completion of her MBA at Instituto de Empresa in 2005, she joined the biotechnology company TiGenix, taking responsibility for corporate development and leading the company’s partnering efforts that culminated in a deal with Takeda worth up to €380M. Following the company’s Nasdaq IPO, Claudia became responsible for investor relations and corporate communications until the completion of the acquisition of TiGenix by Takeda in 2018.

Chief Scientific Officer

qodef-team-image
Chief Scientific Officer

Jose Escribano

Jose is a specialist in viral infectious diseases and in non-fermentative technologies to produce recombinant biologics, with more than 120 scientific contributions in international journals and twelve licensed patents. He is on the editorial board of several virology and biotechnology journals. José is a graduate and Ph.D from Complutense University of Madrid in Veterinary Medicine and he carried out postdoctoral studies in different institutions of USA.

Chief Operations Officer

qodef-team-image
Chief Operations Officer

Romy M. Dalton

Romy has more than 17 years of experience on Molecular Biology and Virology and eleven scientific publications in peer reviewed journals. She has worked first as a researcher and then as a Project Leader at several Biotech Companies. She joined Algenex more than three years ago in the position of Chief Operations Officer and manages the Comercial Agreements, Human Resources, Patent Portfolio and supervises the scientific projects.

Chief Financial Officer

qodef-team-image
Chief Financial Officer

Virginia Gonzalez

Virginia has 20 years experience in different financial positions. After completing her degree in Business Administration at the University of Oviedo, Spain, she joined the finance department of Decathlon. During this period she completed a master in Business Administration. She later joined the biotechnology company TiGenix, a dual listed Company (Nasdaq & Euronext ) recently acquired by Takeda, in which held different roles of responsibility such as finance director and head of controlling and consolidation for more than 13 years. During this period she also completed an Advance Management Program at Instituto de Empresa, Madrid.

Executive Committee

qodef-team-image
Executive Committee Member

Jean Stéphenne

Jean put his skills of Agricultural engineering, specialized in chemistry and bio-industry, at the service of development and production of vaccines throughout his 40 year career within GSK Biologicals group. Under his leadership, the Belgian production site developed into a world-renowned center which integrates research, development, clinical studies, production and global marketing. His experience has led him to hold the Presidency of the Walloon Union of Companies (l'Union wallonne des Entreprises) and to be involved as a board member of many companies.

qodef-team-image
Executive Committee Member

René Aerts

Dr. René Aerts retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previous held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International.<br /> He is the founder of RA-Consultancy BV and holds non-executive and Advisory Board positions at AGC Biologics (Seattle, USA), The Jenner Institute (University of Oxford, UK), ImmunoValley<br /> (Utrecht, The Netherlands) , Schothorst Feed Research BV (Lelystad, The Netherlands) and Alternative Gene Expression Ltd (Madrid, Spain)

qodef-team-image
Executive Committee Member

Claudia D´Augusta

Claudia is a Venture Partner at Ysios and serves on the board of Bonetherapeutix, CVRx and Reneuron. She has over 20 years of experience in the field of corporate finance, capital markets and M&A. Since June 2018 Claudia has been appointed General Manager at TiGenix (now a Takeda’s company). Prior to her appointment as GM, Claudia was Chief Financial Officer of TiGenix leading the company’s IPO on Nasdaq in 2016 and being a member of the Executive Committee. She also served as the Chief Financial Officer of Cellerix and led its merger with TiGenix, a company listed on Euronext. Previous experiences include Deloitte & Touche in Milan and Apax Partners in Madrid. Claudia holds a bachelor’s degree in Economics and a PhD in Business Administration from Bocconi University, Italy.

qodef-team-image
Executive Committee Member

Nicola Zambón

Nicola Zambon - Founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Former director and partner of the private equity firms Investindustrial and Ergon Capital and board member of 15 companies located in various jurisdictions across Europe, Nicola has 23 years of M&A and principal investment experience.

qodef-team-image
Executive Committee Member

Roberto Barzi

Roberto is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently sits on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health), Medinet (UK, clinical services), amongst others.

JAS_Directivos Algenex_RE_18-5 cuadrada

Claudia Jimenez

General Manager

JAS_Directivos Algenex_RE_18-1 cuadrada

Romy M. Dalton

Chief Operations Officer

JAS_Directivos Algenex_RE_18-7 cuadrada

Virginia Gonzalez

Chief Financial Officer

JAS_Directivos Algenex_RE_18-3 cuadrada

Jose Escribano

Chief Scientific Officer

JAS_Directivos Algenex_RE_18-15 cuadrada

Jean Stéphenne

Executive Committee Member

(ex-CEO GSK Biologics)

JAS_Directivos Algenex_RE_18-13 cuadrada

René Aerts

Executive Committee Member

(ex-executive commitee of MSD animal health)

JAS_Directivos Algenex_RE_18-17 cuadrada

Claudia D´Augusta

Executive Committee Member

(CFO Tigenix, Nasdaq listed biotech)

JAS_Directivos Algenex_RE_18-9 cuadrada

Nicola Zambon

Executive Committee Member

(Managing Partner, Cleon Capital)

JAS_Directivos Algenex_RE_18-11 cuadrada

Roberto Barzi

Executive Committee Member

(Managing Partner, Vita)

ALGENEX’s Management Team includes experienced and respected biotechnology professionals providing strong scientific analysis supporting business management’s efforts in innovative technology collaborations and creative business development. ALGENEX’s Team is creating a world-class biotechnology company with a strong track record of success.
ALGENEX IS FINANCED BY A CONSORTIUM OF PRIVATE INVESTORS WHO HAVE COMPLETED A FUNDING ROUND IN Q3 2018
ALGENEX’s Management Team includes experienced and respected biotechnology professionals providing strong scientific analysis supporting business management’s efforts in innovative technology collaborations and creative business development. ALGENEX’s Team is creating a world-class biotechnology company with a strong track record of success.
ALGENEX IS FINANCED BY A CONSORTIUM OF PRIVATE INVESTORS WHO HAVE COMPLETED A FUNDING ROUND IN Q3 2018
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo

A step forward in the baculovirus-based recombinant technologies

Record productivities

Development speed

Cost reductions

Success producing proteins difficult-to-express

10

years of experience in biotechnology

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
160

molecules succesfully produced

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
10

years of experience in biotechnology

160

molecules succesfully produced

10

years of experience in biotechnology

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
160

molecules succesfully produced